Oura, Whoop, Strava: Consumer Health IPO Wave Outlook

Nelson Advisors
4 hours ago
12 min read

Executive Summary

The consumer health technology sector is on the cusp of one of its most consequential public market moments since the 2021 SPAC boom, but this time with real revenue, real retention, and real business models.

Oura filed confidentially for a US IPO on 21st May 2026, Strava submitted its own confidential S-1 in January 2026, and WHOOP declared its $575 Million Series G "the last private round we'll do" in March 2026, with CEO Will Ahmed confirming an IPO is "our next step". Three of the most closely watched names in consumer health technology are converging on the public markets within the same twelve month window.

The combined pre-IPO valuation of all three exceeds $23 Billion, Oura at ~$11 Billion, WHOOP at $10.1 Billion and Strava at ~$2.2 Billion, making this the largest cluster of consumer health listings since the sector was born. Whether public markets will validate these valuations, or subject them to the discipline that rewarded infrastructure-grade digital health businesses (Hinge Health, Tempus AI) while punishing point solutions (Omada), is the defining question of the 2026 IPO cycle.

The Three Candidates: Where They Stand > Oura, Smart Ring, Confidential S-1, $11 Billion Valuation

Oura Health filed confidentially for a US IPO on 21 May 2026, working with Goldman Sachs, Morgan Stanley, JPMorgan, Allen & Co and Jefferies. The Finnish-American company has delivered a revenue trajectory that is genuinely difficult to ignore:

2023: ~$250 Million revenue
2024: $500+ Million (doubled year on year)
2025: ~$1 Billion (doubled again)
2026 guidance: ~$1.5–2 Billion

Total ring sales have surpassed 5.5 Million, more than double the 2.5 Million reported through mid-2024. More than 80% of Oura members renew their subscription after the first year, a retention figure that, when layered on top of hardware margins, gives the company a credible recurring-revenue story that most wearable businesses have never demonstrated at scale.

Paid membership is on course to exceed five million in Q2 2026, a fourfold increase over two years.

Oura's business model sits at the junction of hardware (~80% of revenue) and subscription software (~20%, growing rapidly). Subscriptions now represent approximately 35% of ARR and the company operates at positive EBITDA. The company holds ~52% market share in the dedicated smart ring category and has deployed a systematic IP enforcement campaign, winning ITC import bans against Ultrahuman and RingConn, with active investigations against Samsung, Zepp Health, Reebok and Noise, effectively patenting core smart ring architecture. The ITC moat is a significant competitive differentiator that will feature prominently in its S-1.

In October 2025, Oura raised $875 Million in a Series E at a valuation of ~$10.9 Billion, backed by Fidelity, Iconiq, Whale Rock and Atreides, the investor profile that historically signals an IPO within 12–18 months.

The company has raised over $1.5 Billion in total.

Key IPO tension for Oura: Will public markets classify it as a consumer electronics business (modest revenue multiples) or a health data platform (premium multiples)?

Oura will argue the latter, supported by partnerships with over 1,200 organisations, distribution across 4,600 retail locations and a March 2026 acquisition of Doublepoint (AI gesture recognition, Helsinki). The answer to that categorisation question will likely determine whether its market cap expands or contracts from its $11 Billion private benchmark.

WHOOP > $10.1 Billion, "Next Step is an IPO"

WHOOP raised $575 Million in a Series G at $10.1 Billion, nearly triple its $3.6 Billion valuation from 2021, on 31st March 2026. Founded in 2012 by Will Ahmed at the Harvard Innovation Lab, the Boston-based company makes a screen less health band focused on strain, recovery, and sleep.

The financial case for WHOOP's listing is robust:

Bookings run rate of $1.1 Billion at year-end 2025, up 103% year on year
Operating cash flow positive in 2025
2.5 Million+ active members
Female member growth of 150% year on year as of early 2026, with female users engaging with AI features ~30% more than males, a demographic and monetisation signal of strategic significance

The Series G investor roster is deliberately strategic: Qatar Investment Authority, Mubadala Investment Company (Abu Dhabi), Mayo Clinic, Abbott Laboratories, Collaborative Fund, GP Bullhound Capital, Macquarie Capital, and IVP.

The inclusion of sovereign wealth funds and clinical institutions (Abbott and Mayo Clinic) is an explicit positioning statement that WHOOP is not a fitness gadget, it is healthcare infrastructure.

In May 2025, WHOOP launched WHOOP 5.0 and WHOOP MG, its first medical-grade device incorporating an FDA-cleared ECG, blood pressure insights, and a proprietary "Pace of Aging" feature. In September 2025, it opened Advanced Labs, combining blood testing (65 biomarkers via Quest Diagnostics) with continuous wearable data, reviewed by a clinician and auto-synced to the WHOOP app, to a 350,000-person waitlist.

Pricing runs from $199 to $599 per test cycle. A dedicated women's health blood panel covering hormonal transition markers launched in March 2026. This diagnostics-plus-wearables model is clinically differentiated and represents one of the most interesting convergence stories in consumer health.

CEO Ahmed has not named a listing date but confirmed WHOOP is "doing a lot of the no-regrets work to be a public company" and is hiring more than 600 roles globally. The IPO horizon is estimated at 12–24 months from mid-2026.

Key IPO tension for WHOOP: At $10.1 Billion, WHOOP is already valued at roughly one-quarter of Garmin (~$40 Billion), which competes across a far broader product range.

Public investors will be asked to credit a subscription-plus-hardware health platform at a significant premium over its hardware peers.

The women's health expansion, clinical diagnostics integration and sovereign capital backing all strengthen that narrative, but the path from $1.1 Billion bookings to an EBITDA-positive business at public-market scale needs transparency.

Strava — $2.2 Billion, S-1 Filed, Goldman Sachs Leading

Strava filed confidentially for a US IPO in January 2026, with Goldman Sachs leading and JPMorgan and Morgan Stanley involved. The San Francisco-based social fitness platform, founded in 2009, has 180 million registered users across 190 countries.

Financial profile:

Revenue of ~$415 Million in 2025, up ~18.5% year on year
Revenue grew 50%+ in 2024
Profitable (confirmed by The Information)
Last private valuation: $2.2 Billion (May 2025)
Pre-IPO target valuation estimated at $2–$3 Billion

Strava generates revenue primarily through a freemium subscription model (~$11.99/month or $79.99/year for Strava Summit), with secondary income from brand partnerships and data licensing to municipal planning bodies. The platform acquired Runna (AI-powered training plans) and The Breakaway (cycling community) in 2025 as part of a content-plus-intelligence strategy to drive premium conversion.

The company also hired a new CFO (Matt Anderson) and CMO (Louisa Wee) in August 2025, hires explicitly characterised as IPO preparation signals.

Strava's free-to-premium conversion rate has historically been low, a persistent structural concern. The platform has 180+ Million users but only a fraction pay, meaning the IPO narrative will hinge on demonstrating accelerating subscription economics and defensibility against Apple Fitness+, Garmin Connect, and AI-native health apps.

However, Strava's data asset, 180 Million athletes, Billions of activity files, demographic and geographic granularity, represents a proprietary training dataset for AI that most competitors cannot replicate.

At a $2.2–3 Billion public valuation, Strava is actually the smallest of the three, but arguably the most straightforwardly investable given its profitability, pure software model and high gross margins typical of subscription platforms.

The Market Backdrop: Why Now? A Reopened IPO Window

The 2026 IPO thesis is structurally sound but not without friction. Digital health IPOs effectively froze from 2022 through 2024, before Hinge Health (NYSE, May 2025) and Omada Health (Nasdaq, June 2025) reopened the window.

Hinge Health's stock jumped 17% above its $32 IPO price on debut, achieving a $3 Billion+ market cap; Omada opened 21% above its $19 offering price.

The HealthTech 2.0 cohort including Tempus AI, Waystar, Caris Life Sciences, Hinge Health and Omada, collectively added ~$36.6 Billion in fresh market capitalisation during 2025.

As digital health's 2025 IPO class established proof points, capital has concentrated around a specific archetype: companies with infrastructure-grade status, high net revenue retention, software-like margins, and embedded clinical workflows. The 2026 HealthTech and MedTech IPO outlook has been characterised as "Rational Exuberance", disciplined adherence to unit economics and clinical validation, not speculative growth-at-all-costs.

US IPO markets raised $9.9 Billion in Q1 2026, up 16.4% year on year, though activity slowed in mid-Q1 as geopolitical tensions (Middle East), tech valuation resets, and tariff uncertainty created a "holding pattern". EY's Q1 2026 IPO Trends analysis noted that geopolitical instability and AI-linked valuation corrections constrained listings, but investor confidence in a H2 2026 recovery remains intact.

Wearable Health: A $238 Billion Market in Motion

The global wearable technology market is valued at $238 Billion in 2026, projected to reach $931 Billion by 2035 at a 16.35% CAGR. Grand View Research projects a more conservative $229 Billion by 2033 at a 12.1% CAGR. Apple and Samsung remain the dominant incumbents with 27.4% combined global market share, but Oura and WHOOP are the growth vectors within the premium health segment.

A crucial regulatory tailwind: late-2025 FDA guidance recognising real-world evidence from wearables, provided data integrity and bias mitigation standards are met, is accelerating the shift from "steps and vibes" to clinical-grade monitoring eligible for reimbursement and regulated workflows. This transition is precisely what Oura and WHOOP are positioning for, and it materially upgrades the long-term addressable market for their subscriber economics.

Precedent IPO Comparables

Company	IPO Date	IPO Price	Opening Pop	Market Cap at IPO	Category
Hinge Health	May 2025	$32	+17%	~$3B+	Digital MSK / virtual care
Omada Health	Jun 2025	$19	+21%	~$1.1B	Chronic condition management
Tempus AI	Jun 2024	$37	Strong	Multi-billion	Clinical AI / genomics

These precedents matter. Both Hinge and Omada rewarded investors at debut, but required high gross margins (Hinge: 81%, Omada: 60%) and credible paths to profitability. Oura, WHOOP, and Strava must meet equivalent scrutiny on hardware margins, software ARR growth, and subscription retention quality.

Valuation Framework: Can the $10 Billion Price Tags Hold? Subscription Quality as the Determinant

Post-2022 public markets are valuing consumer health companies on subscription economics, not headline revenue multiples. B2B SaaS revenue multiples have settled at ~5.9x in 2025, with the SaaS Capital Index at 5.5x as of Q1 2026. High-growth outliers running a competitive buyer process can reach 10–12x ARR, but fewer than 5% of private companies get there.

Consumer-facing health platforms (B2C subscription + hardware) trade at a discount to pure B2B SaaS, but a premium to consumer electronics, the exact spectrum on which Oura and WHOOP will be priced.

Key metrics public investors will scrutinise:

Gross margin: Oura's hardware-heavy mix (~80% hardware, 20% subscription) will generate lower blended margins than a pure SaaS peer. Subscription gross margins are likely 70%+, but hardware will dilute blended margins toward 40–55%, below the 60–80% public market benchmark.
Subscription renewal rates: Oura's 80%+ first-year renewal is sector-leading. WHOOP's subscription model (device included in subscription) structurally anchors churn differently but comparably.
Path to EBITDA: Oura is EBITDA positive; WHOOP achieved operating cash flow positive in 2025. Strava is profitable. This separates the trio from the "growth at any cost" cohort that has been punished.
Churn risk: Industry-wide fitness app annual churn can reach 20–37% for retail consumers. Oura's 80%+ renewal argues meaningfully against this. WHOOP's subscription-only model creates switching costs that protect against opportunistic churn.

Oura: Valuation Bull and Bear Case

At $11 Billion private valuation with ~$1.5 Billion in 2026 projected revenue, Oura currently prices at ~7.3x forward revenue. For a hardware-subscription business with 80%+ renewal rates and a 16.35% CAGR sector tailwind, this is defensible but not conservative.

Bull case: The company IPOs at 8–10x 2026 revenue (~$12–15 Billion market cap) on the strength of its IP moat, retention data and clinical partnerships.

Bear case: Public markets apply a consumer electronics discount of 4–5x revenue (~$6–7.5 Billion), especially if Samsung successfully challenges the ITC rulings.

WHOOP: The Boldest Bet

At $10.1 Billion for a $1.1 Billion bookings run rate, WHOOP prices at ~9.2x bookings — a premium that is only sustainable if the market buys the diagnostics platform story. Advanced Labs, the FDA-cleared MG device, and Mayo Clinic/Abbott backing all strengthen that narrative, but hardware economics and the absence of a public revenue disclosure create pricing risk. The IPO is likely 18–24 months away, leaving more time for the clinical thesis to mature.

Strava: The Overlooked Compounder

At $2.2–3 Billion for ~$415 Million in revenue (growing 18–50% depending on year), Strava prices at 5.3–7.2x revenue, the most conservatively valued of the three and the only pure software business. Its profitability, 180 Million user base and data moat position it as a lower-risk entry point for digital health exposure.

The principal risk is premium conversion: the platform's ongoing challenge in converting its massive free user base into paying subscribers is a well-known overhang that will feature prominently in roadshow diligence.

Key Risks and Headwinds

1. Market Timing and Volatility

Q1 2026 was characterised by a lull in IPO activity as geopolitical tension, Middle East conflict, tariff uncertainty and AI valuation resets constrained listings globally. The UK IPO market produced just two listings in Q1 2026. EY confirmed that many anticipated 2026 IPO candidates have concentrated plans in H2 2026. A sustained VIX elevation above 20 (observed since March 2026) creates execution risk for all three listings.

2. Big Tech Competition

Apple has scaled back its "AI doctor" (Project Mulberry) into incremental features inside its Health app, but the Apple Watch, with 229 Million+ units sold, remains a formidable ecosystem anchor. Samsung's Galaxy Ring competes directly with Oura in form factor and Samsung's active ITC challenge to Oura's core ring architecture patents is a live litigation risk. Garmin Connect and Google Fit continue to expand social and health features at no incremental cost to device owners.

3. The Consumer Health Valuation Trap

Public market investors in 2026 are clearly distinguishing "infrastructure-grade" health businesses (embedded in clinical workflows, B2B distribution, reimbursement durability) from "consumer health novelties". Hinge Health's 81% gross margin and employer-payer revenue model earned a premium; consumer wearables with hardware-heavy margins and discretionary spending dependency face a more sceptical audience. The risk for all three companies is being priced as premium consumer electronics rather than healthcare platforms.

4. Churn and Low Conversion

Strava's persistent challenge in converting 180 Million free users into paid subscribers (~$79.99/year) will be a core IPO diligence question. Community sentiment, evidenced by Strava's Reddit community responses to the IPO announcement, is characterised by anxiety about post-IPO monetisation pressure and potential feature restriction. For WHOOP and Oura, the risk is that consumer health tracking fatigue leads to non-renewal — though both companies' current retention data argues against this.

5. Regulatory Risk for Medical-Grade Claims

WHOOP's medical-grade MG device and FDA-cleared ECG, Advanced Labs blood testing, and "Pace of Aging" Healthspan score represent ambitious clinical claims that carry regulatory exposure. Any FDA post-market action, adverse clinical study, or FTC challenge to health claims could materially reset valuation expectations — particularly for a recently listed company with a healthcare platform narrative priced in.

Strategic Implications for M&A and Investors: The IPO Cluster as a Market Signal

The simultaneous movement of Oura, Strava, and WHOOP toward the public markets is not coincidental, it reflects a structural convergence of conditions: IPO window reopening (Hinge/Omada as precedent), institutional capital available for healthcare tech and companies that have finally reached the revenue scale and operational maturity that public markets require. Each S-1, when filed publicly, will reveal margin structures, cohort data and subscriber economics that will immediately reprice private HealthTech comparables across the sector.

For M&A professionals and strategic buyers, the IPO filings serve as involuntary data room disclosures. Competitors, acquirers and strategic investors, including large pharma, insurance groups and device makers, will gain unprecedented transparency into unit economics that have been private for over a decade.

What a Successful IPO Wave Means for European HealthTech

A successful cluster of US consumer health listings would materially improve exit optionality and valuation benchmarks for European HealthTech companies at growth stage. It would validate subscription-plus-hardware business models as public-market investable assets, potentially unlocking a European wave of secondary offerings and strategic M&A activity in digital diagnostics, remote monitoring and women's health, sectors directly adjacent to Oura and WHOOP's positioning.

The WHOOP / Diagnostics Convergence Model

Of the three, WHOOP's combination of continuous biometric monitoring + periodic blood testing (65-biomarker panels, clinician review, app synchronisation) represents the most strategically disruptive model in the 2026 cohort. If Advanced Labs scales alongside the wearable subscription, WHOOP begins to resemble a vertically integrated preventive health company, a structure more analogous to a health services platform (EV/Revenue of 8–12x) than a consumer device business (EV/Revenue of 3–5x). The Abbott and Mayo Clinic investment in the Series G may be the most important signal in the entire funding round: it suggests these institutions see WHOOP as future distribution infrastructure for clinical diagnostics.

Verdict: Is the $10 Billion Wave Real?

Yes — with calibrated expectations. All three companies have real revenue, real retention, and real institutional backing. Oura's confidential S-1 filed 21 May 2026 puts a hard timeline on the wave for 2026. Strava filed in January and is Goldman-led. WHOOP has explicitly stated IPO intent.

The 2025 Hinge/Omada precedents demonstrate that public markets will reward credible digital health businesses, but at a discipline level that rewards gross margin and profitability, not user growth alone.

The collective market cap at IPO for all three could plausibly range from $18–30 Billion, depending on market conditions and how investors categorise each business (consumer electronics vs. health platform).

The central risk is not business quality, it is the macro IPO window and the premium categorisation question. If H2 2026 markets stabilise and WHOOP's clinical narrative lands, the wave will be generational.

If volatility persists and public investors apply consumer electronics multiples to hardware-subscription businesses, the listings will price below private benchmarks, as happened to Fitbit, Peloton, and Jawbone before them.

The differentiator for this cohort is retention data, profitability, and clinical credibility, assets none of the failed wearable IPOs possessed.

Nelson Advisors > European MedTech and HealthTech Investment Banking

Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital

Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb

Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk

#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech